Keeping Pace With Evolving Treatment Paradigms in Advanced Renal Cell Carcinoma: The Nurse's View

i3 Health designates this live activity for a maximum of 1.0 contact hour. Participants should claim only the credit commensurate with the extent of their participation in the activity. To receive an NCPD certificate, complete the form below and return it to the registration table. For questions about your NCPD credit, contact i3 Health at support@i3Health.com.

i3Health
Education on Point™

Date: 9/11/2021 **Location: GLAONS** **Course #: 126-02RCC-01**

Name (please print) _____ Degree _____ # Years in Practice _____

E-mail (where we'll send your NCPD certificate) _____ # Pts with RCC/month _____

Select all that apply:

☐ RN ☐ NP ☐ CRNP ☐ AOCNP® ☐ CNS ☐ OCN® Other: _____

*I attest that I have completed this NCPD activity _____ ***Actual time attended (up to 1.0 hour)** _____
Signature

*REQUIRED FIELDS: SIGNATURE AND ACTUAL TIME ATTENDED MUST BE COMPLETED IN ORDER TO RECEIVE A CERTIFICATE FOR THIS NCPD-CERTIFIED ACTIVITY

Your feedback is critical to future course development. Please take a few minutes to complete this evaluation.

The presentation was: O Excellent O Very Good O Good O Fair O Poor

The presentation was *free of* commercial bias: O Yes O No If No, please explain:_____

The presentation was fair and balanced: O Yes O No

The presentation was evidence based: O Yes O No

This activity supported achievement of each of the following learning objectives:

a. Distinguish the mechanisms of action of immuno-oncology (IO) agents and VEGFR tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC)	O Strongly agree O Agree O No opinion O Disagree O Strongly disagree
b. Differentiate the efficacy and safety profiles of IO and VEGFR TKI therapies for advanced RCC	O Strongly agree O Agree O No opinion O Disagree O Strongly disagree
c. Assess strategies to improve treatment tolerability, control adverse events, and ensure the provision of patient-centered RCC care	O Strongly agree O Agree O No opinion O Disagree O Strongly disagree

I feel that the method of instruction was conducive to learning. O Strongly agree O Agree O No opinion O Disagree O Strongly disagree

I feel that the environment was conducive to learning. O Strongly agree O Agree O No opinion O Disagree O Strongly disagree

Prior to this activity, my knowledge surrounding RCC was: O Very high O High O Moderate O Low O Very low

After this activity, my knowledge surrounding RCC is: O Very high O High O Moderate O Low O Very low

Based on the information I learned during this activity, I feel more confident in treating patients with RCC within my practice.
O Strongly agree O Agree O No opinion O Disagree O Strongly disagree

Knowledge acquired from this activity will be utilized to improve the outcomes of my patients.
O Strongly agree O Agree O No opinion O Disagree O Strongly disagree

Which of the American Board of Nursing Specialties competencies did you perceive as being represented by this activity? **Please check all that apply:**
☐ Implementation ☐ Education ☐ Communication ☐ Professional practice evaluation ☐ Quality of practice

I plan to make the following change(s) to my practice. **Please check all that apply:**
☐ More likely to suggest deferring cytoreductive nephrectomy until after a patient has been treated with systemic therapy
☐ More likely to check for risk factors associated with decreased survival for patients set to undergo cytoreductive nephrectomy
☐ More likely to suggest that patients be considered for immunotherapy-containing regimens regardless of PD-L1 status
☐ More likely to suggest tivozanib for patients with relapsed/refractory advanced RCC
☐ More likely to suggest nivolumab/cabozantinib for patients with untreated advanced RCC
☐ More likely to suggest that patients be considered for treatment with pembrolizumab/axitinib even if their RCC has sarcomatoid features
☐ More likely to monitor for hypertension, taste changes, mucositis, dyspepsia, myelosupression, and hand-foot syndrome in patients taking VEGF-targed therapy
☐ More likely to monitor for pruritis, myocarditis, adrenal insufficiency, rash, pneumonitis, colitis, and hepatitis in patients taking immunotherapy
☐ More likely to monitor for diarrhea, hypertension, hypothyroidism, and fatigue in patients taking pembrolizumab/axitinib
☐ More likely to educate patients taking immunotherapy regimens on reporting immune-related adverse events
☐ More likely to refer patients with RCC to clinical trials

What barrier(s) do you face in your practice that impact your ability to provide optimal care? Please check all that apply:
☐Cost ☐Time constraints ☐Staff/system resources ☐Reimbursement/insurance issues ☐Organizational/institutional limitations
☐Lack of applicable guidelines for my current practice/patients ☐Conflicting evidence ☐Patient adherence/compliance issues
☐Treatment-related adverse events ☐Other (please explain): _____

Do you plan to seek additional education on the management of RCC within the next 3 to 6 months? O Yes O No O I do not know

What specific action(s) do you plan to take as a result of participating in this activity? Please check all that apply:
☐ Share the activity with colleagues
☐ Read national guidelines (eg, NCCN) on managing RCC to enhance my clinical competence
☐ Review the activity slide set to enhance my clinical competence
☐ Review and/or recommend modifications to my institution's protocols/practice guidelines
☐ Request further education on the topic with my institution's educational coordinator
☐ Discuss related concerns with my mentor/attending faculty about managing RCC in my practice
☐ Align my patient education strategies with national guidelines/published evidence
☐ Become involved in RCC research/clinical trials
☐ Discuss studies mentioned in the activity during a journal club or other forum to stimulate discussion/debate with peers
☐ Other (please explain): _____